Cyanotech Corp.

As of November 9, 2022, Cyanotech Corp. is considered overvalued and has a risky valuation outlook due to poor financial metrics and significant underperformance compared to the S&P 500.

As of October 1, 2023, there is insufficient technical data for Cyanotech Corp. to determine a bullish or bearish outlook.

As of October 15, 2023, Cyanotech Corp. is considered attractive and undervalued, with a P/E ratio of 15.2 and a P/B ratio of 1.8, outperforming peers like Algae Farms and Ocean Harvest, and its stock performance has exceeded the Sensex.

As of March 2022, the management team of Cyanotech Corp. includes Mr. Michael Davis as the Independent Chairman and Dr. Gerald Cysewski as the CEO and Executive Vice Chairman, along with Independent Directors Ms. Nancy Katz, Mr. Walter Menzel, Mr. David Mulder, and Mr. David Vied.

Cyanotech Corporation produces natural products from microalgae for the nutritional supplements market and operates as a micro-cap company with a market cap of $2.57 million. As of December 2024, it reported net sales of $6 million but no net profit.

As of Jun 18, Cyanotech Corp. has a market capitalization of 2.57 million and reported net sales of 23.88 million with a net profit of -4.65 million over the latest four quarters. Shareholder's funds are at 11.81 million, and total assets are 25.11 million.